Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Inclusion Criteria:

Inclisiran Cohort Patients eligible for inclusion in this study must meet all of the following criteria.

1. Confirmed diagnosis of primary hypercholesterolemia or mixed dyslipidemia

2. Age ≥ 18 years at baseline

3. Initiated treatment with inclisiran according to the decision of both physician andpatient

4. Signed informed consent(s) must be obtained prior to participation in the study

SoC Historical Cohort Patients eligible for inclusion in this study must meet all of the following criteria.

1. Confirmed diagnosis of primary hypercholesterolemia or mixed dyslipidemia, withwhich reference to LDL-C > 70 mg/dL (1.8 mmol/L)

2. Age ≥ 18 years

3. Compliance with the standard lipid-lowering therapy, which is defined as a changefrom prior lipid-lowering therapy to an optimal lipid-lowering regimen, with thedate of compliance with standard lipid-lowering therapy after January 1, 2017 as theindex date

4. With available LDL-C test at baseline, which is defined as the closest LDL-C test tothe index date within 6 months prior to the index date

5. With available LDL-C test on D90 (90±60 days) or D330 (330±90 days) after the indexdate

Exclusion Criteria:

Inclisiran Cohort Patients meeting any of the following criteria are not eligible for inclusion in this study.

1. Treatment with monoclonal antibodies directed towards PCSK9 within 90 days beforefirst visit (V1)

2. Severe hepatic impairment (Child-Pugh class C)

3. Severe renal impairment (eGFR ≤ 30 mL/min), and/or on hemodialysis

4. Participation in any cardiovascular clinical trial, concurrent or within the last 30days of the baseline

5. Females who are pregnant or nursing, or who are preparing for pregnancy

6. Hypersensitivity to the active substance or to any of the excipients of inclisiransolution

SoC Historical Cohort Patients meeting any of the following criteria are not eligible for inclusion in this study.

1. Treatment with monoclonal antibodies directed towards PCSK9 during research period

2. Severe hepatic impairment (Child-Pugh class C)

3. Severe renal impairment, (eGFR ≤ 30 mL/min), and/or on hemodialysis

4. Participation in any cardiovascular clinical trial during research period

5. Females who are pregnant or nursing during research period